Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open-label, Dose Escalation Study of HST5040 in Subjects With Propionic or Methylmalonic Acidemia Followed by a Randomized, Double-blind, Placebo-controlled, 2-period Crossover Study and an Open-label, Long-term Extension Study

NCT04732429 is registered in ClinicalTrials.gov with HemoShear Therapeutics as lead sponsor.

NCT NCT04732429
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04732429 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open-label, Dose Escalation Study of HST5040 in Subjects With Propionic or Methylmalonic Acidemia Followed by a Randomized, Double-blind, Placebo-controlled, 2-period Crossover Study and an Open-label, Long-term Extension Study
Lead sponsor
HemoShear Therapeutics
Phase
Phase 2
Overall status
Terminated
Start date
March 15, 2021
Completion date
October 20, 2023
Enrollment
26 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

methylmalonic acidemia, propionic acidemia